-
Publication Venue For
-
A Mixed-Methods Study of the Impact of Mild Cognitive Impairment Diagnosis on Patient and Care Partner Perception of Health Risks..
85:1175-1187.
2022
-
Cerebrovascular Function, Vascular Risk, and Lifestyle Patterns in Resistant Hypertension..
87:345-357.
2022
-
Use of Cognitive Testing, Questionnaires, and Plasma Biomarkers to Quantify Cognitive Impairment in an Aging Pet Dog Population..
87:1367-1378.
2022
-
Validity of the Web-Based, Self-Directed, NeuroCognitive Performance Test in Mild Cognitive Impairment..
86:1131-1136.
2022
-
APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid..
79:511-530.
2021
-
Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease..
84:1323-1335.
2021
-
Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction..
80:1281-1297.
2021
-
Hemochromatosis Mutations, Brain Iron Imaging, and Dementia in the UK Biobank Cohort..
79:1203-1211.
2021
-
A Prospective Longitudinal Study of Caregivers of Community Dwelling Persons with Severe Dementia (PISCES): Study Protocol..
75:403-416.
2020
-
Co-Prevalence of Alzheimer's Disease and Age-Related Macular Degeneration Established by Histopathologic Diagnosis..
76:207-215.
2020
-
Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease..
74:563-578.
2020
-
How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?.
74:625-636.
2020
-
Late-Life Cognitive Trajectories and their Associated Lifestyle Factors..
73:1555-1563.
2020
-
Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial..
77:1793-1803.
2020
-
The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction..
75:1319-1328.
2020
-
A δ Homolog for Dementia Case Finding with Replication in the Alzheimer's Disease Neuroimaging Initiative..
67:67-79.
2019
-
Association Between Insulin Resistance, Plasma Leptin, and Neurocognition in Vascular Cognitive Impairment..
71:921-929.
2019
-
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers..
67:911-921.
2019
-
Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology..
72:35-43.
2019
-
Accuracy of Inferred APOE Genotypes for a Range of Genotyping Arrays and Imputation Reference Panels..
64:49-54.
2018
-
Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension..
66:1095-1104.
2018
-
Dual-Task Gait and Alzheimer's Disease Genetic Risk in Cognitively Normal Adults: A Pilot Study..
64:1137-1148.
2018
-
Effectiveness of a Personalized Brain-Computer Interface System for Cognitive Training in Healthy Elderly: A Randomized Controlled Trial..
66:127-138.
2018
-
Homocysteine and Cerebral Atrophy: The Epidemiology of Dementia in Singapore Study..
62:877-885.
2018
-
Recommendations for the Nomenclature of Cognitive Change Associated with Anaesthesia and Surgery-20181..
66:1-10.
2018
-
Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment..
64:137-148.
2018
-
Serum SHBG Levels are not Associated with Longitudinal Cognitive Decline in Mild Cognitive Impairment..
55:1123-1130.
2017
-
The Association Between Retinal Neuronal Layer and Brain Structure is Disrupted in Patients with Cognitive Impairment and Alzheimer's Disease..
54:585-595.
2016
-
The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial..
52:1299-1310.
2016
-
Validation of the Total Cerebrovascular Disease Burden Scale in a Community Sample..
52:1021-1028.
2016
-
Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians..
49:991-1003.
2016
-
Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment..
49:1191.
2016
-
Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data..
46:695-702.
2015
-
Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease..
45:45-56.
2015
-
Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment..
48:293-301.
2015
-
Subcortical Atrophy in Cognitive Impairment and Dementia..
48:813-823.
2015
-
Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs..
48:647-665.
2015
-
Retinal microvasculature in Alzheimer's disease..
42 Suppl 4:S339-S352.
2014
-
Human apolipoprotein E2 promotes parenchymal amyloid deposition and neuronal loss in vasculotropic mutant amyloid-β protein Tg-SwDI mice..
31:359-369.
2012
-
Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly..
32:357-372.
2012
-
The importance of being connected..
24:247-251.
2011
-
Genome-wide scan of copy number variation in late-onset Alzheimer's disease..
19:69-77.
2010
-
Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA)..
18:665-675.
2009
-
The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited..
17:807-815.
2009